Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ScPvs25
- Development stage
- Phase 1
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
ScPvs25 is an experimental recombinant protein transmission-blocking vaccine (TBV) developed by the National Institute of Allergy and Infectious Diseases (NIAID) to prevent the transmission of *Plasmodium vivax* malaria. The vaccine consists of the Pvs25 protein, which is expressed on the surface of the malaria parasite during its zygote and ookinete stages within the mosquito midgut. The protein is produced using a *Saccharomyces cerevisiae* (yeast) expression system. ScPvs25 is designed to induce the production of specific antibodies in the human host. When a mosquito bites a vaccinated individual and ingests these antibodies, they bind to the Pvs25 protein on the parasite's surface, inhibiting its development within the mosquito and preventing the mosquito from transmitting the disease to other humans. In clinical trials, ScPvs25 has been formulated with the adjuvant Montanide ISA 51 to enhance immunogenicity.
- Other names
- Pvs25 vaccinePvs-25 vaccinePvs 25 vaccineSaccharomyces cerevisiae-expressed Pvs25Plasmodium vivax transmission-blocking vaccine
02
Targets
Pvs25 (Plasmodium vivax ookinete surface protein 25)
Beyond the preview
Go deeper on ScPvs25.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ScPvs25.